Shane Schaffer is the co-founder, Chairman, and CEO of Cingulate Therapeutics, a Phase 3 clinical-stage biopharmaceutical company based in Kansas City, Kansas. The company specializes in developing branded, next-generation pharmaceutical products for Attention Deficit/Hyperactivity Disorders (ADHD), as well as for anxiety disorders and insomnia.

A veteran in the pharmaceutical industry with 25 years of experience, he has an extensive background in drug development and commercialization. His strategic leadership and entrepreneurial approach have greatly influenced various business operations such as product launches, brand planning, joint venture brand management, life cycle management, and market development, making him a prominent figure in biopharmaceutical and marketing.

He earned his doctoral degree in Pharmacy from the University of Kansas in 1999 and subsequently completed a postdoctoral pharmaceutical industry fellowship at Rutgers University’s College of Pharmacy. During his fellowship, he worked with Pfizer Worldwide Marketing and Morris Plains, where he assumed pivotal roles in marketing management and strategy development.

He was a marketing manager at Pfizer Worldwide Marketing in New York, NY. He initiated the Global Communications Intranet to facilitate effective communication between medical and marketing teams. He also played a key role in creating and implementing the Pfizer Medical and Academic Partnership in Pain Management.

He was a project manager and external research manager at Morris Plains, New Jersey, leading advanced sales training and management development programs. He was instrumental in managing and supervising the initiation of Phase IV Medical Research across all marketed brands.

He has held senior managerial positions at major pharmaceutical companies, including Pfizer, Novartis, and Sanofi. At Novartis, he managed the Ritalin® LA and Focalin™ segments from their inception, significantly enhancing the ADHD franchise with practical strategies that greatly improved market penetration and brand recognition.

After his tenure at Novartis, he continued to impact the industry at Sanofi, leading strategic initiatives during the company’s mergers and joint ventures, notably with the promotional campaigns for Avapro and Avalide. He also managed promotion and contract strategies for Hyalgan, Eligard, and Arixtra, efforts that were recognized with multiple Sanofi Star Awards for his leadership and relationship management.